Stocktoria

CITIUS ONCOLOGY, INC. CTOR

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-10-14

CITIUS ONCOLOGY, INC. statistics & valuation

Market cap$57.6M
P / B1.3×
Return on equity-55.2%
Return on capital-45.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20222023202320242025
Operating margin (%)
20222023202320242025
Return on equity (%)
110.20% -49.70% 10.60% -45.80% -55.20% 20222023202320242025
Shares outstanding
2.4M 67.5M 6.6M 71.6M 83.5M 20222023202320242025
Net debt ($)
20222023202320242025
Share buybacks ($)
20222023202320242025
Return on assets (%)
0.60% -26.60% 3.30% -25.10% -24.50% 20222023202320242025
Free cash flow margin (%)
20222023202320242025
Debt / equity (×)
20222023202320242025
EPS ($)
$0.12 -$0.19 $0.27 -$0.31 -$0.34 20222023202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2023FY2022
Return on assets-24.5%-25.1%3.3%-26.6%0.6%
Return on equity-55.2%-45.8%10.6%-49.7%110.2%
Current ratio0.560.340.030.3711.85

Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.